and the like in general the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention the deuterated analog of the invention may be prepared by conventional methods for chemical synthesis e g those described in the working examples the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals also one compound of the invention may be converted to another compound of the invention using conventional methods the end products of the reactions described herein may be isolated by conventional techniques e g by extraction crystallisation distillation chromatography etc wo 01 46145 wo 01 46146 wo 2005 121087 wo 2007 042295 wo 2008 127188 and wo 2008 155357 all describe substituted 4 phenyl n alkyl piperazines and 4 phenyl n alkyl piperidines reported to be modulators of dopamine neurotransmission and to be useful in treatment of symptoms of various disorders of the central nervous system the deuterated analog of the invention is considered useful for the same medical indications as described in these publications and these publications therefore are incorporated by reference neurological indications contemplated according to these publications include the treatment of huntington 39 s disease and other movement disorders as well as movement disorders induced by drugs therefore in a preferred embodiment the invention relates to the use of the deuterated analog of the invention for use as a medicament for the treatment of huntington 39 s disease viewed from another aspect the invention provides deuterated analogs for use as medicaments therefore in another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention while.